Shandong Buchang Pharmaceuticals Partners with Vietnamese MKT for Exclusive Adalimumab Biosimilar Distribution in Vietnam
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today plans to sign a “Distribution, Marketing...
European Commission Approves Sanofi’s Subcutaneous Sarclisa (Isatuximab) Across All Multiple Myeloma Indications Based on Phase III IRAKLIA Data
The European Commission announced this week its approval of Sanofi’s (NASDAQ: SNY) Sarclisa (isatuximab) subcutaneous...
Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug...
Bayer Announces Consumer Health Leadership Restructuring with New Global and U.S. Appointments
Bayer AG (ETR: BAYN) announced today a strategic leadership restructuring within its Consumer Health division,...
RemeGen Secures Dual NMPA Approvals for Tai’ai (Telitacicept) in Sjögren’s Syndrome and IgA Nephropathy, Expanding First-in-Class BLyS/APRIL Inhibitor Franchise
RemeGen Co., Ltd. (HKG: 9995, SHA: 688331) announced today that China’s National Medical Products Administration...
Konruns Pharmaceutical to Acquire 30% Stake in Huamao Pharma for $28.2 Million, Achieving Vertical Integration from API to Finished Formulation
Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced today its strategic acquisition of a 30% stake...
Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors
Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...
Zai Lab Secures NMPA Approval for Tivdak (Tisotumab Vedotin) in Recurrent or Metastatic Cervical Cancer Based on Phase III innovaTV 301 Data
Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced today that China’s National Medical Products Administration (NMPA)...
Otsuka Pharmaceutical Secures NMPA Approval for Voyxact (Sibeprenlimab) in IgA Nephropathy Based on Pivotal Phase III VISIONARY Data
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced today that China’s National Medical Products Administration (NMPA)...
Hangzhou Highlightll Pharmaceutical Files for Hong Kong IPO with Seven-Candidate Pipeline Targeting Autoimmune and Neurodegenerative Diseases
Hangzhou Highlightll Pharmaceutical Co., Ltd., a clinical-stage biopharmaceutical company founded in 2017, has filed a...
Boji Medical Raises $66 Million Through Private Placement to Expand Integrated CRO and TCM Innovation Platform
Boji Medical Technology Co., Ltd. (SHE: 300404), a leading China-based Clinical Research Organization (CRO), announced...
Pfizer Secures FDA Approval for Marstacimab Expanded Indication in Hemophilia A and B Across Pediatric and Adult Populations
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has...
MSD and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study of Trodelvy-KEYTRUDA Combination in First-Line NSCLC
Merck & Co., Inc. (MSD; NYSE: MRK) and Gilead Sciences, Inc. (NASDAQ: GILD) announced today...
J&J to Acquire Firefly Bio for $1 Billion, Adding Proprietary DAC Platform Targeting KRAS-Driven Tumors
Johnson & Johnson (J&J, NYSE: JNJ) announced today a definitive agreement to acquire Firefly Bio,...
Nurix and Roche Forge $2.3 Billion Global Collaboration for BTK Degrader Bexobrutideg Across Oncology, Immunology and Neurology
Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Roche (SWX: ROP, OTCMKTS: RHHBY) announced today a comprehensive...
GSK to Acquire Nuvalent for $10.6 Billion, Adding Breakthrough Lung Cancer Therapies to Oncology Portfolio
GlaxoSmithKline plc (GSK) (NYSE: GSK) announced today a definitive agreement to acquire Nuvalent, Inc. (NASDAQ:...
PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
PegBio Co., Ltd. (HKG: 2565) announced receipt of the first milestone payment of HKD 61...
Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
Sino Medical Sciences Technology Inc. (SHA: 688108) announced it has received marketing approval from Colombia’s...
Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...
Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...